False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis.

Autor: Franklin J; The University of Texas Southwestern Medical Center Medical School, Dallas, TX, USA. jordanfranklin66@gmail.com.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. jordanfranklin66@gmail.com., Hayes J; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Knippa E; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Dogan B; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (3), pp. 507-520. Date of Electronic Publication: 2024 Mar 14.
DOI: 10.1007/s10549-024-07259-0
Abstrakt: Purpose: Mitigating false negative imaging studies remains an important issue given its association with worse morbidity and mortality in patients with breast cancer. We aimed to identify risk factors that predispose to false negative breast imaging exams.
Methods: In an IRB-approved, HIPAA compliant retrospective study, we identified all patients who were diagnosed with breast cancer within 365 days of a negative imaging study assessed as BI-RADS 1-3 between January 1, 2014 and January 31, 2020. A matched cohort based on mammographic breast density was created from randomly selected studies with BI-RADS 4-5 designation that yielded breast cancer at pathology within the same time frame. Patient and cancer characteristics, prior personal history of breast cancer and gene mutation status were collected from patient charts. Pearson chi-squared and Student's t-test on two independent groups with significance at < 0.05 was used for statistical analysis.
Results: We identified 155 false negative studies of 129 missed cancers and 128 breast density matched true positive cancers. False negative studies were screening mammograms in 57.42% (89/155), diagnostic mammograms in 29.68% (46/155), ultrasounds in 6.45% (10/155) and MRIs in 6.45% (10/155). Rates of personal (41.09% vs. 18.75%, p < 0.001) and family history of breast cancer (68.22% vs. 49.21%, p = 0.002) were higher in the false negative cohort and remained significant when asymptomatic MRI-detected cancers were removed.
Conclusion: Our findings suggest that supplemental screening may be useful in breast cancer survivors.
(© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
Databáze: MEDLINE
Externí odkaz: